William Kelly, MD, discusses the safety and efficacy signals seen with sacituzumab govitecan in a phase 2 study of patients with recurrent glioblastoma.
William Kelly, MD
Advertisement
William Kelly, MD, is a medical oncologist specializing in neuro-oncology and thoracic oncology at the University of Texas Health San Antonio MD Anderson Cancer Center and an assistant professor in the Division of Hematology and Oncology at the Mays Cancer Center.
Articles by William Kelly, MD
Advertisement
Latest Updated Articles
Dr Kelly on Early Efficacy Signals and Safety With Sacituzumab Govitecan in Recurrent GlioblastomaPublished: April 7th 2025 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
3
Dr Spencer on First-Line Chemo Selection in Metastatic Pancreatic Adenocarcinoma
4
2025 Data Across Gynecologic, Lung, and Hematologic Cancers Reshape Treatment Landscapes
5